Operational Costs Compared: SG&A Analysis of Bio-Techne Corporation and Mesoblast Limited

A Decade of SG&A Trends in Biotech Giants

In the ever-evolving biotech industry, operational efficiency is paramount. Over the past decade, Bio-Techne Corporation and Mesoblast Limited have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. Bio-Techne's SG&A expenses have surged by over 550% from 2014 to 2024, reflecting its aggressive expansion and investment in operational capabilities. In contrast, Mesoblast Limited has experienced a more modest increase of around 4% in the same period, indicating a more conservative approach to operational spending.

Key Insights

• Bio-Techne Corporation: From 2014 to 2024, Bio-Techne's SG&A expenses grew from approximately 6% to 40% of its total operational costs, highlighting its strategic focus on scaling operations.
• Mesoblast Limited: Despite fluctuations, Mesoblast's SG&A expenses remained relatively stable, peaking in 2015 and gradually declining thereafter.

These trends underscore the diverse strategies employed by biotech firms in managing operational costs.